Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Article
  • Open Access

10 February 2024

12 Pages

Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma

,
,
,
,
,
,
and
1
Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA
2
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA
3
Department of Pathology and Anatomical Sciences, University at Buffalo, Buffalo, NY 14203, USA
4
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA

Simple Summary

Non-small cell lung cancer accounts for most lung cancer. In recent years, immunotherapy, especially with PD1/PDL1 inhibitors such as pembrolizumab, has emerged as an important treatment modality. The exploration of new avenues such as tumor biomarker analysis has proven beneficial in determining treatment responsiveness. Various studies have shown a positive association between distinct tumor characteristics and the response to pembrolizumab. In this study, we established that the presence of higher proportions of viable tumor cells and increased tumor-infiltrating lymphocytes in non-small cell lung cancer show favorable responses to treatment with pembrolizumab.

Abstract

Pembrolizumab, a widely used immune checkpoint inhibitor (ICI), has revolutionized the treatment of non-small cell lung cancer (NSCLC). Identifying unique tumor characteristics in patients likely to respond to pembrolizumab could help the clinical adjudication and development of a personalized therapeutic strategy. In this retrospective study, we reviewed the clinical data and pathological features of 84 NSCLC patients treated with pembrolizumab. We examined the correlation between the clinical and demographic characteristics and the tumor histopathologic features obtained before immunotherapy. The response to pembrolizumab therapy was evaluated via the Response Evaluation Criteria in Solid Tumors (RECIST). The clinical data and cancer tissue characteristics were assessed and compared among three groups according to the following RECIST: the responsive group (RG), the stable disease group (SD), and the progressive disease group (PD), where the RG comprised patients with either a complete response (CR) or a partial response (PR). The overall survival rate of the RG group was significantly higher than the SD and PD groups. In addition, the percentage of pre-treatment viable tumor cell content in the RG and SD groups was significantly higher. At the same time, the extracellular stroma proportion was significantly lower than that of the PD group. The number of tumor-infiltrating lymphocytes (TILs) in the RG group was significantly higher than in the PD group. There were no significant differences in tumor necrosis, the stroma composition, PD-L1 expression level (TPS 1–49% vs. ≥50%), and treatment response. In conclusion, our population of NSCLC patients who experienced positive treatment responses to pembrolizumab therapy had a better prognosis compared to patients with either SD or PD. Moreover, the relative proportions of viable tumor cells to tumor-associated lymphocytes were associated with responsiveness to treatment. It is expected that larger prospective clinical studies will further validate these findings.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.